口腔替比培南-阿维巴坦在鼠分枝杆菌肺感染模型中的活性。
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.
机构信息
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
出版信息
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. doi: 10.1128/aac.01459-22. Epub 2023 Jan 23.
The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection. The results suggest that tebipenem-avibactam presents an attractive oral drug candidate pair for the treatment of M. abscessus pulmonary disease and could inform the design of clinical trials.
β-内酰胺类药物替比培南与β-内酰胺酶抑制剂阿维巴坦联合使用对脓肿分枝杆菌具有强大的杀菌活性。在这里，我们报告称，相应的口服前药替比培南 pivoxil 和阿维巴坦 ARX-1796 的联合使用在脓肿分枝杆菌肺部感染的小鼠模型中显示出疗效。结果表明，替比培南-阿维巴坦组合是一种有吸引力的治疗脓肿分枝杆菌肺病的口服候选药物对，并为临床试验的设计提供了信息。
Zotero 插件